DUBLIN–(BUSINESS WIRE)–The “Hospital-Acquired Disease Testing Market Analysis by Test Type (Pneumonia Stents, Urinary Tract Infection, Blood Stream Infection, Surgical Site Infection, Methicillin-Resistant Staphylococcus Aureus), and by Region – Forecast to 2029” report has been added to ResearchAndMarkets.com’s offering.
The global hospital-acquired disease testing market size is estimated to be USD 1,500.4 million in 2021 and is expected to witness a CAGR of 20.81% during the forecast period.
This exhaustive research report focuses on market size and forecast at global, segmental, regional and country level along with key market trends and dynamics from 2021 to 2029.
Increasing incidences of different medical conditions are a key driver for the growth of the global hospital-acquired disease testing market.
Additionally, growing length of stay in the hospital, negligence by the hospital staff during the patient’s stay, and increase in multi-drug resistant organisms (MDROs) are some of the other drivers propelling the market growth. Nevertheless, limited insurance coverage for such diseases and the presence of ambiguous management frameworks are expected to restrain the global market growth.
By Test Type
Based on test type, the market is segmented into pneumonia stents, urinary tract infection, bloodstream infection, surgical site infection, methicillin-resistant staphylococcus aureus, and others.
In 2021, the urinary tract infection segment accounted for the substantial revenue share with lucrative CAGR during the forecast period.
This is due to the factor stating that UTI is the most common hospital-acquired disease worldwide. Surgical site infection segment is projected to grow at a profitable CAGR during the forecast period. This is attributed to negligence on part of the hospital staff during the patient’s stay.
Regional Insights
In 2021, North America accounted for the highest revenue share in the global market and is expected to maintain its dominance during the forecast period.
This is attributed to the growing aged population, strict regulatory norms, improving healthcare infrastructure, and the increase in number of hospital stays along with the growing risk of contracting hospital-acquired disease.
Asia Pacific market is projected to exhibit the fastest CAGR over the forecast period owing to the less stringent regulations, escalating demand for advanced medication and treatment, and growing medical tourism in this region.
The leading players operating in the hospital-acquired disease testing industry are adopting various strategies including R&D investments, adoption of advanced techniques, mergers & acquisitions, and regional expansions to capture a maximum revenue share.
Some of the key players in the hospital-acquired disease testing market are
- Luminex Corporation (U.S.)
- Diatherix Laboratories (U.S.)
- Life Technologies (U.S.)
- Cantel Medical Corporation (U.S.)
- Meridian Biosciences Inc. (U.S.)
- Nordion Inc. (Canada)
- Qiagen GmbH (Germany)
- Hoffmann-La Roche AG (Switzerland)
- Biomerieux (France)
- Cepheid Inc. (U.S.)
Scope of the Report
Hospital-Acquired Disease Testing Market, By Test Type (Revenue, USD Million, 2021 – 2029)
- Pneumonia Stents
- Urinary Tract Infection
- Blood Stream Infection
- Surgical Site Infection
- Methicillin-resistant Staphylococcus Aureus
- Others
Hospital-Acquired Disease Testing Market, By Region (Revenue, USD Million, 2021 – 2029)
North America
- U.S.
- Canada
Europe
- Germany
- France
- UK
- Spain
- Italy
- Russia
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
Middle East & Africa
- South Africa
- Saudi Arabia
- Rest of MEA
For more information about this report visit https://www.researchandmarkets.com/r/3uklqk
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
